|
US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
DK1417207T3
(en)
*
|
2000-08-04 |
2005-12-27 |
Warner Lambert Co |
Process for Preparation of 2- (4-Pyridyl) Amino-6-Dialkyloxyphenyl-Pyrido [2,3-d] Pyrimidin-7-One
|
|
JP2004505974A
(en)
*
|
2000-08-04 |
2004-02-26 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
Method for producing 2- (4-pyridyl) amino-6-dialkyloxyphenylpyrido [2,3-d] pyrimidin-7-one
|
|
HRP20030624B1
(en)
*
|
2001-02-12 |
2007-03-31 |
F. Hoffmann - La Roche Ag |
6-substituted pyrido-pyrimidines
|
|
KR100540623B1
(en)
*
|
2001-02-26 |
2006-01-11 |
다나베 세이야꾸 가부시키가이샤 |
Pyridopyrimidine or Naphthyridine Derivatives
|
|
WO2003000270A1
(en)
*
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel pyridopyrimidones and uses thereof
|
|
US20050154046A1
(en)
*
|
2004-01-12 |
2005-07-14 |
Longgui Wang |
Methods of treating an inflammatory-related disease
|
|
WO2003062236A1
(en)
|
2002-01-22 |
2003-07-31 |
Warner-Lambert Company Llc |
2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
|
|
CA2492112A1
(en)
|
2002-08-06 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
|
|
US7129351B2
(en)
|
2002-11-04 |
2006-10-31 |
Hoffmann-La Roche Inc. |
Pyrimido compounds having antiproliferative activity
|
|
JP4666256B2
(en)
*
|
2002-12-10 |
2011-04-06 |
小野薬品工業株式会社 |
Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
|
|
KR100864393B1
(en)
|
2003-04-10 |
2008-10-20 |
에프. 호프만-라 로슈 아게 |
Pyrimido compounds
|
|
DE602004017474D1
(en)
*
|
2003-07-11 |
2008-12-11 |
Warner Lambert Co |
ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR
|
|
CA2532965C
(en)
|
2003-07-22 |
2013-05-14 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
|
AU2004261250B2
(en)
|
2003-07-29 |
2009-02-26 |
Xenon Pharmaceuticals Inc. |
Pyridyl derivatives and their use as therapeutic agents
|
|
WO2005047284A1
(en)
*
|
2003-11-13 |
2005-05-26 |
F. Hoffmann-La Roche Ag |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
US7968557B2
(en)
*
|
2004-02-14 |
2011-06-28 |
Novartis Ag |
Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors
|
|
EP1718645A1
(en)
*
|
2004-02-18 |
2006-11-08 |
Warner-Lambert Company LLC |
2-(pyridin-3-ylamino)-pyrido 2,3-d pyrimidin-7-ones
|
|
BRPI0509580A
(en)
*
|
2004-03-30 |
2007-11-27 |
Pfizer Prod Inc |
signal transduction inhibitor combinations
|
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
|
CA2727841A1
(en)
*
|
2004-06-11 |
2005-12-22 |
Japan Tobacco Inc. |
5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido [2, 3-d] pyrimidine derivatives and related compounds
|
|
WO2006053043A2
(en)
|
2004-11-10 |
2006-05-18 |
Genzyme Corporation |
Methods of treating diabetes mellitus
|
|
US20060142312A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Pfizer Inc |
C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
|
|
KR101346886B1
(en)
*
|
2005-01-21 |
2014-01-02 |
아스텍스 테라퓨틱스 리미티드 |
Pharmaceutical compounds
|
|
JP2008528469A
(en)
*
|
2005-01-21 |
2008-07-31 |
アステックス・セラピューティクス・リミテッド |
Combination of pyrazole kinase inhibitor and further anticancer agent
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
US20080161251A1
(en)
*
|
2005-01-21 |
2008-07-03 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
|
AR054425A1
(en)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
|
|
WO2006090853A1
(en)
|
2005-02-25 |
2006-08-31 |
Ono Pharmaceutical Co., Ltd. |
Nitrogenous heterocyclic compound and medicinal use thereof
|
|
AR053346A1
(en)
*
|
2005-03-25 |
2007-05-02 |
Glaxo Group Ltd |
COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
|
|
PE20100741A1
(en)
*
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
|
|
EP1879573B1
(en)
|
2005-05-10 |
2012-12-19 |
Incyte Corporation |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
|
KR100734837B1
(en)
*
|
2005-09-16 |
2007-07-03 |
한국전자통신연구원 |
Multi biometrics system and method thereof
|
|
EP1931667A1
(en)
*
|
2005-09-28 |
2008-06-18 |
Ranbaxy Laboratories Limited |
Pyrido-pyridimidine derivatives useful as antiinflammatory agents
|
|
ES2432046T3
(en)
*
|
2005-10-07 |
2013-11-29 |
Exelixis, Inc. |
PI3Kalfa inhibitor pyridopyrimidinones
|
|
EA201200669A1
(en)
*
|
2005-10-07 |
2012-11-30 |
Экселиксис, Инк. |
PYRIDOPYRIMIDINONE INHIBITORS PI3Kα
|
|
JP2009536186A
(en)
*
|
2006-05-08 |
2009-10-08 |
アステックス・セラピューティクス・リミテッド |
Pharmaceutical combinations of diazole derivatives for cancer treatment
|
|
SI2032134T1
(en)
|
2006-05-09 |
2015-10-30 |
Genzyme Corporation |
Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
|
|
CA2662768A1
(en)
*
|
2006-09-08 |
2008-03-20 |
Pfizer Products Inc. |
Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
|
|
WO2008032162A1
(en)
|
2006-09-15 |
2008-03-20 |
Pfizer Products Inc. |
Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
|
|
EP1914234A1
(en)
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
|
CA2665384A1
(en)
*
|
2006-10-16 |
2008-04-24 |
Gpc Biotech Inc. |
Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
|
|
WO2008150260A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Gpc Biotech, Inc. |
8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
|
|
CN101535308A
(en)
*
|
2006-11-09 |
2009-09-16 |
霍夫曼-拉罗奇有限公司 |
Substituted 6-phenyl-pyrido [2,3-D] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
AU2008307516B2
(en)
|
2007-10-05 |
2011-11-17 |
Genzyme Corporation |
Method of treating polycystic kidney diseases with ceramide derivatives
|
|
WO2009085185A1
(en)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
US8389533B2
(en)
|
2008-04-07 |
2013-03-05 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
|
MY171866A
(en)
|
2008-07-08 |
2019-11-05 |
Incyte Holdings Corp |
1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
|
JP2011529500A
(en)
|
2008-07-28 |
2011-12-08 |
ジェンザイム コーポレーション |
Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular diseases
|
|
MY150560A
(en)
*
|
2008-08-22 |
2014-01-30 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
|
CN102231984A
(en)
*
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
|
|
CN102231983A
(en)
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
|
CN107935983A
(en)
|
2008-10-03 |
2018-04-20 |
简詹姆公司 |
2 amide groups propyl alcohol type glucosylceramide synthase inhibitor
|
|
PA8852901A1
(en)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
PROTEIN CINASE INHIBITORS
|
|
ES2552386T3
(en)
|
2009-04-03 |
2015-11-27 |
F. Hoffmann-La Roche Ag |
Propane-1-sulfonic acid {3- [5- (4-chloro-phenyl) -1H-pyrrole [2,3-b] pyridin-3-carbonyl] -2,4-difluoro-phenyl} -amide compositions and uses thereof
|
|
EP2429566B1
(en)
|
2009-05-13 |
2016-01-06 |
The University of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
EP2474540A4
(en)
*
|
2009-08-31 |
2013-03-13 |
Nippon Chemiphar Co |
Gpr119 agonist
|
|
AU2010303218A1
(en)
*
|
2009-10-09 |
2012-05-10 |
Afraxis Holdings, Inc. |
8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8H)-ones for the treatment of CNS disorders
|
|
EA201290210A1
(en)
|
2009-11-06 |
2012-10-30 |
Плексксикон, Инк. |
CONNECTIONS AND METHODS OF KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION
|
|
JP5797664B2
(en)
*
|
2009-12-18 |
2015-10-21 |
テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ |
Substituted pyrido [2,3-d] pyrimidin-7 (8H) -ones and their therapeutic use
|
|
PH12012501361A1
(en)
|
2009-12-31 |
2012-10-22 |
Centro Nac De Investigaciones Oncologicas Cnio |
Tricyclic compounds for use as kinase inhibitors
|
|
KR101830455B1
(en)
|
2010-04-13 |
2018-02-20 |
노파르티스 아게 |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
|
TWI619713B
(en)
|
2010-04-21 |
2018-04-01 |
普雷辛肯公司 |
Compounds and methods for kinase regulation and their indications
|
|
EP2580217A4
(en)
*
|
2010-06-10 |
2014-06-18 |
Afraxis Holdings Inc |
6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
|
|
EP2580320B1
(en)
|
2010-06-14 |
2018-08-01 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
BR112013002375B1
(en)
|
2010-08-05 |
2020-05-12 |
Temple University - Of The Commonwealth System Of Higher Education |
COMPOUND, SAME PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION, AND, USES OF A COMPOUND
|
|
CA2815084C
(en)
|
2010-10-25 |
2017-05-09 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
AU2011329763A1
(en)
|
2010-11-17 |
2013-05-09 |
Brigham And Women's Hospital |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
WO2012098387A1
(en)
|
2011-01-18 |
2012-07-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
|
|
SMT201900112T1
(en)
|
2011-02-07 |
2019-02-28 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
|
EP2688887B1
(en)
*
|
2011-03-23 |
2015-05-13 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
|
JP2014522396A
(en)
|
2011-05-27 |
2014-09-04 |
テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション |
Substituted 2-benzylidene-2H-benzo [b] [1,4] thiazin-3 (4H) -one, derivatives thereof and therapeutic use thereof
|
|
KR20140138910A
(en)
*
|
2012-03-14 |
2014-12-04 |
루핀 리미티드 |
Heterocyclyl compounds
|
|
EP3216792B1
(en)
|
2012-03-29 |
2020-05-27 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
ES2984771T3
(en)
|
2012-06-13 |
2024-10-31 |
Incyte Holdings Corp |
Substituted tricyclic compounds as FGFR inhibitors
|
|
RU2679130C2
(en)
|
2012-07-11 |
2019-02-06 |
Блюпринт Медсинс Корпорейшн |
Inhibitors of fibroblast growth factor receptor
|
|
WO2014022830A2
(en)
|
2012-08-03 |
2014-02-06 |
Foundation Medicine, Inc. |
Human papilloma virus as predictor of cancer prognosis
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
AU2013302519B2
(en)
|
2012-08-17 |
2017-11-02 |
Concert Pharmaceuticals, Inc. |
Deuterated baricitinib
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US20150353542A1
(en)
|
2013-01-14 |
2015-12-10 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
ES2694787T3
(en)
*
|
2013-02-21 |
2018-12-27 |
Pfizer Inc. |
Solid forms of a selective CDK4 / 6 inhibitor
|
|
EA032094B1
(en)
|
2013-03-15 |
2019-04-30 |
Консерт Фармасьютикалс, Инк. |
Deuterated palbociclib
|
|
WO2014144740A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
|
EP2968291B1
(en)
|
2013-03-15 |
2025-04-16 |
Pharmacosmos Holding A/S |
Hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
ES2657451T3
(en)
|
2013-04-19 |
2018-03-05 |
Incyte Holdings Corporation |
Bicyclic heterocyclics as FGFR inhibitors
|
|
CN104470921B
(en)
*
|
2013-05-17 |
2017-05-03 |
上海恒瑞医药有限公司 |
Pyridopyrimidine derivatives, their preparation method and their application in medicine
|
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
|
MX2016005297A
(en)
|
2013-10-25 |
2016-08-12 |
Blueprint Medicines Corp |
Inhibitors of the fibroblast growth factor receptor.
|
|
EP4512480A3
(en)
*
|
2013-12-20 |
2025-05-07 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of cdk and erk inhibitors
|
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
ES2687477T3
(en)
|
2013-12-31 |
2018-10-25 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and its use
|
|
WO2015108992A1
(en)
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
|
US20150297608A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents
|
|
ES2873959T3
(en)
|
2014-05-28 |
2021-11-04 |
Piramal Entpr Ltd |
Pharmaceutical combination comprising a CDK inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer
|
|
KR20170031241A
(en)
*
|
2014-07-24 |
2017-03-20 |
베타 파마, 인크. |
2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
|
|
AU2015296322B2
(en)
*
|
2014-07-26 |
2019-09-19 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
|
|
US20170217962A1
(en)
*
|
2014-07-31 |
2017-08-03 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of palbociclib
|
|
WO2016024232A1
(en)
*
|
2014-08-11 |
2016-02-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
|
|
US20170240543A1
(en)
*
|
2014-08-14 |
2017-08-24 |
Sun Pharmaceutical Industries Limited |
Crystalline forms of palbociclib
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
CN105111201B
(en)
*
|
2014-10-16 |
2017-01-11 |
上海页岩科技有限公司 |
5-methyl-2-(pyridinyl-2-amino)-8H-pyrido[2,3-d]pyrimidin-7-ketone compounds
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
WO2016066420A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Sandoz Ag |
Crystalline forms of palbociclib monohydrochloride
|
|
CN105622638B
(en)
*
|
2014-10-29 |
2018-10-02 |
广州必贝特医药技术有限公司 |
Pyrimidine or pyridopyridine ketone compounds and its preparation method and application
|
|
CN105616418A
(en)
*
|
2014-11-07 |
2016-06-01 |
江苏豪森药业集团有限公司 |
Pharmaceutical preparation containing cyclin inhibitor, and preparation method thereof
|
|
PL3218005T3
(en)
|
2014-11-12 |
2023-05-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
CN104447743B
(en)
|
2014-11-26 |
2016-03-02 |
苏州明锐医药科技有限公司 |
The preparation method of Pa Boxini
|
|
CN104496983B
(en)
*
|
2014-11-26 |
2016-06-08 |
苏州明锐医药科技有限公司 |
A kind of preparation method of Pa Boxini
|
|
WO2016090257A1
(en)
*
|
2014-12-05 |
2016-06-09 |
Crystal Pharmatech Inc. |
Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
|
|
WO2016092442A1
(en)
*
|
2014-12-08 |
2016-06-16 |
Sun Pharmaceutical Industries Limited |
Processes for the preparation of crystalline forms of palbociclib acetate
|
|
CN105732615B
(en)
*
|
2014-12-31 |
2018-05-01 |
山东轩竹医药科技有限公司 |
Cdk kinase inhibitors
|
|
JP6581197B2
(en)
|
2014-12-31 |
2019-09-25 |
深▲セン▼市薬欣生物科技有限公司Ｓｈｅｎｚｈｅｎ Ｐｈａｒｍａｃｉｎ Ｃｏ．， Ｌｔｄ． |
Pharmaceutical composition and method for producing the same
|
|
CN104610254B
(en)
*
|
2015-01-26 |
2017-02-01 |
新发药业有限公司 |
Low-cost preparation method for palbociclib
|
|
CZ201589A3
(en)
|
2015-02-11 |
2016-08-24 |
Zentiva, K.S. |
Palbociclib salt solid forms
|
|
TWI690533B
(en)
|
2015-02-12 |
2020-04-11 |
南北兄弟藥業投資有限公司 |
Compounds as cdk small-molecule inhibitors and uses thereof
|
|
MA41551A
(en)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
|
|
CN107438607B
(en)
|
2015-02-20 |
2021-02-05 |
因赛特公司 |
Bicyclic heterocycles as FGFR inhibitors
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
AR104068A1
(en)
|
2015-03-26 |
2017-06-21 |
Hoffmann La Roche |
COMBINATIONS OF A 3-KINASE PHOSFOINOSYTIDE INHIBITOR COMPOSITE AND A CDK4 / 6 INHIBITOR COMPOUND FOR CANCER TREATMENT
|
|
EP3078663A1
(en)
|
2015-04-09 |
2016-10-12 |
Sandoz Ag |
Modified particles of palbociclib
|
|
WO2016156070A1
(en)
|
2015-04-02 |
2016-10-06 |
Sandoz Ag |
Modified particles of palbociclib
|
|
CN106795159B
(en)
*
|
2015-04-22 |
2018-12-28 |
江苏恒瑞医药股份有限公司 |
A crystalline form of a cyclin-dependent protein kinase inhibitor and a preparation method thereof
|
|
TWI696617B
(en)
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
Certain protein kinase inhibitor
|
|
JP6400196B2
(en)
*
|
2015-05-29 |
2018-10-03 |
帝人ファーマ株式会社 |
Pyrido [3,4-d] pyrimidine derivatives and pharmaceutically acceptable salts thereof
|
|
PE20180395A1
(en)
|
2015-06-04 |
2018-02-28 |
Pfizer |
SOLID DOSAGE FORMS OF PALBOCICLIB
|
|
CN104892604B
(en)
*
|
2015-06-19 |
2016-08-24 |
北京康立生医药技术开发有限公司 |
A kind of synthetic method of CDK4 inhibitor
|
|
CN106699785A
(en)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
2-(N-oxide pyridine-2-ylamino)-pyrido[2,3-d]pyrimidin-7-one compound as CDK4/6 inhibitor
|
|
EP3331881B1
(en)
|
2015-08-05 |
2019-05-15 |
ratiopharm GmbH |
New crystalline form and acetic acid adducts of palbociclib
|
|
CN105085517B
(en)
*
|
2015-08-06 |
2016-11-23 |
天津华洛康生物科技有限公司 |
A kind of crystal type Pa Boxini free alkali hydrate and preparation method thereof
|
|
CN105130986B
(en)
*
|
2015-09-30 |
2017-07-18 |
广州科擎新药开发有限公司 |
Pyrimidine or pyridopyridine ketone compounds and its application
|
|
HU230962B1
(en)
|
2015-10-28 |
2019-06-28 |
Egis Gyógyszergyár Zrt. |
Salts of palbociclib
|
|
CN106632311B
(en)
|
2015-11-02 |
2021-05-18 |
上海科胜药物研发有限公司 |
Preparation method of Palbociclib crystal form A and crystal form B
|
|
WO2017083582A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CN105418603A
(en)
*
|
2015-11-17 |
2016-03-23 |
重庆莱美药业股份有限公司 |
Method for preparing high-purity palbociclib and reaction intermediate of palbociclib
|
|
CN106810536A
(en)
|
2015-11-30 |
2017-06-09 |
甘李药业股份有限公司 |
A kind of kinases inhibitor and preparation method thereof and medical usage
|
|
CN108699055B
(en)
*
|
2015-12-13 |
2020-10-23 |
杭州英创医药科技有限公司 |
Heterocyclic compounds used as anticancer drugs
|
|
US10662186B2
(en)
|
2015-12-31 |
2020-05-26 |
Shanghai Pharmaceuticals Holding Co., Ltd. |
Substituted pyrimidines as cyclin-dependent kinase inhibitors
|
|
CN105418609B
(en)
*
|
2015-12-31 |
2017-06-23 |
山东大学 |
4 (1,2,3 triazole substituted anilinic) pyridines a pair of horses going side by side pyrimidone derivatives and preparation method and application
|
|
CN106967061A
(en)
*
|
2016-01-13 |
2017-07-21 |
常州方楠医药技术有限公司 |
Handkerchief wins the salt in XiLin, crystal formation and preparation method thereof
|
|
WO2017130219A1
(en)
|
2016-01-25 |
2017-08-03 |
Mylan Laboratories Limited |
Amorphous solid dispersion of palbociclib
|
|
WO2017145054A1
(en)
|
2016-02-24 |
2017-08-31 |
Lupin Limited |
Modified particles of crystalline palbociclib free base and process for the preparation thereof
|
|
US11077110B2
(en)
|
2016-03-18 |
2021-08-03 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
|
CN107266421B
(en)
*
|
2016-04-08 |
2020-12-04 |
正大天晴药业集团股份有限公司 |
Substituted benzimidazole derivatives
|
|
CN107286180B
(en)
*
|
2016-04-11 |
2019-07-02 |
上海勋和医药科技有限公司 |
Heteropyridopyrimidinone derivatives as CDK inhibitors and their applications
|
|
WO2017185031A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
|
|
CN106336411B
(en)
*
|
2016-04-27 |
2018-03-06 |
上海医药集团股份有限公司 |
The preparation technology and purposes of CDK4/6 inhibitor Pa Boxini high-purity raw medicines
|
|
CN105949189B
(en)
*
|
2016-06-05 |
2017-09-22 |
童明琼 |
A kind of preparation method for being used to treat the Pa Boxini of breast cancer
|
|
BR112018077136A2
(en)
|
2016-07-01 |
2019-04-30 |
G1 Therapeutics, Inc. |
compound, and methods for treating a disorder associated with abnormal cell proliferation and for reducing the effect of chemotherapy on healthy cells.
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
US10807978B2
(en)
|
2016-07-04 |
2020-10-20 |
Dr. Reddy's Laboratories Limited |
Process for preparation of palbociclib
|
|
US10597393B2
(en)
|
2016-07-07 |
2020-03-24 |
Plantex Ltd. |
Solid state forms of Palbociclib dimesylate
|
|
PT3497103T
(en)
*
|
2016-08-15 |
2021-06-17 |
Pfizer |
Pyridopyrimdinone cdk2/4/6 inhibitors
|
|
IL264950B2
(en)
|
2016-08-23 |
2024-01-01 |
Eisai R&D Man Co Ltd |
Combination therapies for the treatment of hepatocellular carcinoma
|
|
CN110022900A
(en)
|
2016-09-08 |
2019-07-16 |
蓝图药品公司 |
Combination of fibroblast growth factor receptor 4 inhibitor and cyclin-dependent kinase inhibitor
|
|
US10710999B2
(en)
|
2016-10-07 |
2020-07-14 |
Mylan Laboratories Limited |
Polymorph of an intermediate for palbociclib synthesis
|
|
EP3804724B1
(en)
|
2016-10-20 |
2022-12-07 |
Pfizer Inc. |
Cdk inhibitors for treating pah
|
|
WO2018073574A1
(en)
|
2016-10-20 |
2018-04-26 |
Cipla Limited |
Polymorphic forms of palbociclib
|
|
CN106565707B
(en)
*
|
2016-11-03 |
2019-01-04 |
杭州科巢生物科技有限公司 |
Pa Boxini novel synthesis
|
|
EP3538148A1
(en)
|
2016-11-08 |
2019-09-18 |
Dana-Farber Cancer Institute |
Compositions and methods of modulating anti-tumor immunity
|
|
WO2018091999A1
(en)
|
2016-11-16 |
2018-05-24 |
Pfizer Inc. |
Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
|
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
|
LT3546456T
(en)
*
|
2016-11-28 |
2022-03-10 |
Teijin Pharma Limited |
PYRIDINE [3,4-D] PYRIMIDINE DERIVATIVES OR SOLVATE CRYSTALS
|
|
CA3043561A1
(en)
|
2016-11-28 |
2018-05-31 |
Teijin Pharma Limited |
Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
|
|
WO2018108167A1
(en)
|
2016-12-16 |
2018-06-21 |
基石药业 |
Cdk4/6 inhibitor
|
|
IL267795B2
(en)
|
2017-01-06 |
2023-02-01 |
G1 Therapeutics Inc |
Combined treatment for cancer
|
|
CN108191857B
(en)
*
|
2017-01-24 |
2020-10-23 |
晟科药业（江苏）有限公司 |
6-substituted pyrido [2,3-D ] pyrimidines as protein kinase inhibitors
|
|
US10729692B2
(en)
*
|
2017-02-26 |
2020-08-04 |
Institute For Cancer Research |
Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
|
|
EP3589634A4
(en)
*
|
2017-03-03 |
2020-08-12 |
Auckland Uniservices Limited |
FGFR KINASE INHIBITORS AND PHARMACEUTICAL USES
|
|
WO2018160909A1
(en)
|
2017-03-03 |
2018-09-07 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CA3056701A1
(en)
|
2017-03-16 |
2018-09-20 |
Eisai R&D Management Co., Ltd. |
Combination therapies for the treatment of breast cancer
|
|
CN108658855A
(en)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
A kind of nitrogenous dicyclic compound and its preparation method and application
|
|
CN108658854A
(en)
*
|
2017-03-28 |
2018-10-16 |
中国海洋大学 |
A kind of alkaloid compound and preparation method thereof and application as marine antifoulant
|
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
AR111960A1
(en)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
|
|
MX2019015177A
(en)
|
2017-06-16 |
2020-02-07 |
Beta Pharma Inc |
Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-m ethoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl )acrylamide and salts thereof.
|
|
CA3067873A1
(en)
|
2017-06-29 |
2019-01-03 |
G1 Therapeutics, Inc. |
Morphic forms of g1t38 and methods of manufacture thereof
|
|
EA036060B1
(en)
*
|
2017-07-17 |
2020-09-21 |
Пфайзер Инк. |
Pyridopyrimdinone cdk2/4/6 inhibitors
|
|
WO2019020715A1
(en)
|
2017-07-28 |
2019-01-31 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
CN109384767B
(en)
*
|
2017-08-08 |
2020-05-05 |
江苏恒瑞医药股份有限公司 |
A kind of preparation method of pyridopyrimidine derivatives and intermediate thereof
|
|
EP3676404B1
(en)
|
2017-08-31 |
2025-09-03 |
Novartis AG |
Methods of selecting a treatment for breast cancer patients
|
|
CN107488175A
(en)
*
|
2017-09-04 |
2017-12-19 |
上海微巨实业有限公司 |
A kind of pa wins the preparation method of XiLin key intermediate
|
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
CA3085366A1
(en)
|
2017-12-22 |
2019-06-27 |
Petra Pharma Corporation |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
CN108586452A
(en)
*
|
2018-01-12 |
2018-09-28 |
重庆市碚圣医药科技股份有限公司 |
A kind of synthetic method of Pa Boxini intermediates
|
|
MX2020007959A
(en)
|
2018-01-29 |
2020-09-18 |
Beta Pharma Inc |
2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof.
|
|
CN108218861B
(en)
*
|
2018-02-05 |
2019-07-23 |
黑龙江中医药大学 |
A kind of drug and preparation method thereof preventing and treating diabetes
|
|
CA3090493A1
(en)
|
2018-02-06 |
2019-08-15 |
The Board Of Trustees Of The University Of Illinois |
Substituted benzothiophene analogs as selective estrogen receptor degraders
|
|
US20200405809A1
(en)
|
2018-02-27 |
2020-12-31 |
Pfizer Inc. |
Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor
|
|
TWI877770B
(en)
|
2018-02-27 |
2025-03-21 |
美商英塞特公司 |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
|
FI3788047T3
(en)
|
2018-05-04 |
2024-11-02 |
Incyte Corp |
SOLID FORM OF FGFT INHIBITOR AND METHODS FOR THEIR PREPARATION
|
|
JP7568512B2
(en)
|
2018-05-04 |
2024-10-16 |
インサイト・コーポレイション |
Salt of FGFR inhibitor
|
|
ES2968899T3
(en)
|
2018-05-14 |
2024-05-14 |
Pfizer |
Formulation of the oral solution
|
|
US11168089B2
(en)
|
2018-05-18 |
2021-11-09 |
Incyte Corporation |
Fused pyrimidine derivatives as A2A / A2B inhibitors
|
|
PL3802529T3
(en)
|
2018-05-24 |
2024-03-25 |
Synthon B.V. |
A process for making palbociclib
|
|
CR20240054A
(en)
|
2018-07-05 |
2024-02-26 |
Incyte Corp |
FUSED PYRAZINE DERIVATIVES AS A2A/A2B INHIBITORS (Div. 2021-71)
|
|
KR20210035211A
(en)
|
2018-07-23 |
2021-03-31 |
에프. 호프만-라 로슈 아게 |
How to treat cancer with PI3K inhibitor GDC-0077
|
|
EP3840756A4
(en)
|
2018-08-24 |
2022-04-27 |
G1 Therapeutics, Inc. |
IMPROVED SYNTHESIS OF 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE
|
|
JP6952747B2
(en)
|
2018-09-18 |
2021-10-20 |
ファイザー・インク |
Combination of TGFβ inhibitor and CDK inhibitor for cancer treatment
|
|
JP2022504388A
(en)
|
2018-10-08 |
2022-01-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Cancer treatment method using PI3K alpha inhibitor and metformin
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
WO2020114519A1
(en)
*
|
2018-12-07 |
2020-06-11 |
杭州英创医药科技有限公司 |
Heterocyclic compound as cdk-hdac dual pathway inhibitor
|
|
AU2019407426A1
(en)
|
2018-12-21 |
2021-07-22 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
|
AU2019413360B2
(en)
|
2018-12-28 |
2025-05-22 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
CA3124574A1
(en)
*
|
2018-12-28 |
2020-07-02 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
TWI829857B
(en)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
|
|
WO2020157709A1
(en)
|
2019-02-01 |
2020-08-06 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
|
CA3130210A1
(en)
*
|
2019-02-15 |
2020-08-20 |
Incyte Corporation |
Cyclin-dependent kinase 2 biomarkers and uses thereof
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
WO2020180959A1
(en)
|
2019-03-05 |
2020-09-10 |
Incyte Corporation |
Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
WO2020223469A1
(en)
|
2019-05-01 |
2020-11-05 |
Incyte Corporation |
N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
CA3141452A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
US20220241412A1
(en)
|
2019-05-24 |
2022-08-04 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
CN112010844B
(en)
*
|
2019-05-31 |
2023-07-25 |
中国药科大学 |
Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor
|
|
TW202112767A
(en)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
CN112094272A
(en)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
CDK kinase inhibitors
|
|
CN113993505B
(en)
*
|
2019-06-20 |
2023-12-12 |
江苏恒瑞医药股份有限公司 |
Pharmaceutical composition and preparation method thereof
|
|
CN110143948B
(en)
*
|
2019-06-21 |
2021-05-14 |
上海博悦生物科技有限公司 |
CDK4/6 inhibitor, pharmaceutical composition, preparation method and application thereof
|
|
EP3993785A4
(en)
|
2019-07-07 |
2023-08-02 |
Olema Pharmaceuticals, Inc. |
Regimens of estrogen receptor antagonists
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
JP2022543062A
(en)
|
2019-08-01 |
2022-10-07 |
インサイト・コーポレイション |
Dosing Regimens for IDO Inhibitors
|
|
WO2021030537A1
(en)
|
2019-08-14 |
2021-02-18 |
Incyte Corporation |
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
|
|
US12208095B2
(en)
|
2019-08-26 |
2025-01-28 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
MX2022004390A
(en)
|
2019-10-11 |
2022-08-08 |
Incyte Corp |
Bicyclic amines as cdk2 inhibitors.
|
|
WO2021076602A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN112759589B
(en)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
Pyrimidopyridinones and their use
|
|
CN114901659A
(en)
|
2019-11-26 |
2022-08-12 |
施万生物制药研发Ip有限责任公司 |
Fused pyrimidinone compounds as JAK inhibitors
|
|
EP4069218A1
(en)
|
2019-12-03 |
2022-10-12 |
Genentech, Inc. |
Combination therapies for treatment of breast cancer
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
AU2020395185A1
(en)
|
2019-12-04 |
2022-06-02 |
Incyte Corporation |
Derivatives of an FGFR inhibitor
|
|
CN114901666B
(en)
|
2019-12-16 |
2025-01-14 |
卢内拉生物技术有限公司 |
Selective CDK4/6 inhibitor-type cancer treatment drugs
|
|
IL293932A
(en)
*
|
2019-12-16 |
2022-08-01 |
Lunella Biotech Inc |
Selective cancer drugs cdk4/6 inhibitors
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TW202146017A
(en)
|
2020-03-05 |
2021-12-16 |
美商輝瑞股份有限公司 |
Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
|
|
CN115697343A
(en)
|
2020-03-06 |
2023-02-03 |
因赛特公司 |
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
|
|
WO2021183994A1
(en)
*
|
2020-03-13 |
2021-09-16 |
Prosenestar Llc |
Pyrido[2,3-d]pyrimidin-7(8h)-ones as cdk inhibitors
|
|
CN114245753A
(en)
*
|
2020-03-27 |
2022-03-25 |
江苏康宁杰瑞生物制药有限公司 |
Combination of an anti-HER 2 antibody and a CDK inhibitor for tumor therapy
|
|
JP2021167301A
(en)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Simultaneous treatment with CDK4 / 6 and CDK2 inhibitors to suppress tumor adaptation to CDK2 inhibitors
|
|
BR112022020841A2
(en)
|
2020-04-16 |
2023-05-02 |
Incyte Corp |
CAST TRICYCLIC KRAS INHIBITORS
|
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
CA3173678A1
(en)
|
2020-05-19 |
2021-11-25 |
Jay Copeland Strum |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
|
US20230132667A1
(en)
*
|
2020-05-28 |
2023-05-04 |
University Of Washington |
Drug-like molecules and methods for the therapeutic targeting of viral rna structures
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
CN113880809B
(en)
|
2020-07-03 |
2022-10-18 |
盛世泰科生物医药技术(苏州)有限公司 |
Pyrimidine derivative and preparation method and application thereof
|
|
EP4181920B1
(en)
|
2020-07-15 |
2025-09-10 |
Pfizer Inc. |
Kat6 inhibitor and combinations for breast cancer treatment
|
|
US20230321042A1
(en)
|
2020-07-20 |
2023-10-12 |
Pfizer Inc. |
Combination therapy
|
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
|
WO2022063119A1
(en)
*
|
2020-09-24 |
2022-03-31 |
南京济群医药科技股份有限公司 |
Composition and drug of palbociclib isethionate
|
|
CN114306245A
(en)
|
2020-09-29 |
2022-04-12 |
深圳市药欣生物科技有限公司 |
Pharmaceutical composition of amorphous solid dispersion and preparation method thereof
|
|
WO2022072783A1
(en)
|
2020-10-02 |
2022-04-07 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of kras
|
|
WO2022091001A1
(en)
|
2020-10-29 |
2022-05-05 |
Pfizer Ireland Pharmaceuticals |
Process for preparation of palbociclib
|
|
WO2022123419A1
(en)
|
2020-12-08 |
2022-06-16 |
Pfizer Inc. |
Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
|
|
CN112569361B
(en)
*
|
2020-12-30 |
2023-01-10 |
扬子江药业集团上海海尼药业有限公司 |
Piperazine Bai Xili dry suspension composition and preparation method thereof
|
|
WO2022155941A1
(en)
|
2021-01-25 |
2022-07-28 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors
|
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
|
WO2022206888A1
(en)
|
2021-03-31 |
2022-10-06 |
Qilu Regor Therapeutics Inc. |
Cdk2 inhibitors and use thereof
|
|
TW202304459A
(en)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
EP4352060A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202313611A
(en)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
Tricyclic heterocycles as fgfr inhibitors
|
|
KR20240021239A
(en)
*
|
2021-06-09 |
2024-02-16 |
티와이케이 메디슨즈, 인코포레이티드 |
Compounds used as CDK kinase inhibitors and their uses
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
WO2023283213A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
JP2024529347A
(en)
|
2021-07-14 |
2024-08-06 |
インサイト・コーポレイション |
Tricyclic Compounds as Inhibitors of KRAS
|
|
MX2024001266A
(en)
|
2021-07-26 |
2024-04-16 |
Celcuity Inc |
1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4, 6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer.
|
|
JP2024534187A
(en)
|
2021-08-31 |
2024-09-18 |
インサイト・コーポレイション |
Naphthyridine Compounds as Inhibitors of KRAS - Patent application
|
|
CN113683612B
(en)
*
|
2021-09-07 |
2022-06-17 |
山东铂源药业股份有限公司 |
Preparation method of palbociclib
|
|
CN118119393A
(en)
*
|
2021-09-14 |
2024-05-31 |
甘李药业股份有限公司 |
Medical application of CDK4/6 inhibitor
|
|
US12030883B2
(en)
|
2021-09-21 |
2024-07-09 |
Incyte Corporation |
Hetero-tricyclic compounds as inhibitors of KRAS
|
|
EP4408536A1
(en)
|
2021-10-01 |
2024-08-07 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
AU2022367432A1
(en)
|
2021-10-14 |
2024-05-02 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
|
TW202320792A
(en)
|
2021-11-22 |
2023-06-01 |
美商英塞特公司 |
Combination therapy comprising an fgfr inhibitor and a kras inhibitor
|
|
WO2023102184A1
(en)
|
2021-12-03 |
2023-06-08 |
Incyte Corporation |
Bicyclic amine compounds as cdk12 inhibitors
|
|
EP4444315A1
(en)
|
2021-12-10 |
2024-10-16 |
Eli Lilly and Company |
Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
|
|
US12084453B2
(en)
|
2021-12-10 |
2024-09-10 |
Incyte Corporation |
Bicyclic amines as CDK12 inhibitors
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
WO2023111810A1
(en)
|
2021-12-14 |
2023-06-22 |
Pfizer Inc. |
Combination therapies and uses for treating cancer
|
|
WO2023114264A1
(en)
|
2021-12-15 |
2023-06-22 |
Eli Lilly And Company |
Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
|
|
AR128043A1
(en)
|
2021-12-22 |
2024-03-20 |
Incyte Corp |
SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR THEIR PREPARATION
|
|
WO2023168686A1
(en)
|
2022-03-11 |
2023-09-14 |
Qilu Regor Therapeutics Inc. |
Substituted cyclopentanes as cdk2 inhibitors
|
|
TW202341982A
(en)
|
2021-12-24 |
2023-11-01 |
大陸商上海齊魯銳格醫藥研發有限公司 |
Cdk2 inhibitors and use thereof
|
|
CN114456180B
(en)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
Compounds and pharmaceutical preparations and applications for treating and/or preventing malignant tumors
|
|
EP4490151A1
(en)
|
2022-03-07 |
2025-01-15 |
Incyte Corporation |
Solid forms, salts, and processes of preparation of a cdk2 inhibitor
|
|
HU231594B1
(en)
*
|
2022-05-10 |
2025-03-28 |
Egis Gyógyszergyár Zrt. |
Pharmaceutical composition comprising palbociclib and letrozole
|
|
WO2023250430A1
(en)
|
2022-06-22 |
2023-12-28 |
Incyte Corporation |
Bicyclic amine cdk12 inhibitors
|
|
EP4302832A1
(en)
|
2022-07-07 |
2024-01-10 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing glucono delta lactone
|
|
EP4302755B1
(en)
|
2022-07-07 |
2025-08-20 |
Lotus Pharmaceutical Co., Ltd. |
Palbociclib formulation containing an amino acid
|
|
US20240101557A1
(en)
|
2022-07-11 |
2024-03-28 |
Incyte Corporation |
Fused tricyclic compounds as inhibitors of kras g12v mutants
|
|
CN117430597A
(en)
*
|
2022-07-14 |
2024-01-23 |
浙江同源康医药股份有限公司 |
Compounds used as CDK4 kinase inhibitors and uses thereof
|
|
CN119604288A
(en)
|
2022-07-29 |
2025-03-11 |
辉瑞大药厂 |
Dosage regimens comprising KAT6 inhibitors for treating cancer
|
|
CN120112291A
(en)
|
2022-08-31 |
2025-06-06 |
阿尔维纳斯运营股份有限公司 |
Dosing regimen of estrogen receptor degraders
|
|
JP2024067010A
(en)
|
2022-11-02 |
2024-05-16 |
ペトラ・ファーマ・コーポレイション |
Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of diseases - Patents.com
|
|
WO2024100236A1
(en)
|
2022-11-11 |
2024-05-16 |
Astrazeneca Ab |
Combination therapies for the treatment of cancer
|
|
CN120344527A
(en)
*
|
2022-12-16 |
2025-07-18 |
上海岸阔医药科技有限公司 |
Compounds and uses thereof
|
|
WO2024133726A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024132652A1
(en)
|
2022-12-22 |
2024-06-27 |
Synthon B.V. |
Pharmaceutical composition comprising palbociclib
|
|
WO2024201334A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof
|
|
WO2024201340A1
(en)
|
2023-03-30 |
2024-10-03 |
Pfizer Inc. |
Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
|
|
US20240390340A1
(en)
|
2023-04-18 |
2024-11-28 |
Incyte Corporation |
Pyrrolidine kras inhibitors
|
|
TW202446371A
(en)
|
2023-04-18 |
2024-12-01 |
美商英塞特公司 |
2-azabicyclo[2.2.1]heptane kras inhibitors
|
|
WO2024231275A1
(en)
|
2023-05-05 |
2024-11-14 |
Astrazeneca Ab |
Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
|
|
WO2024235844A1
(en)
|
2023-05-12 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods of preventing on-target genotoxicity induced by nucleases
|
|
WO2024254245A1
(en)
|
2023-06-09 |
2024-12-12 |
Incyte Corporation |
Bicyclic amines as cdk2 inhibitors
|
|
WO2025051337A1
(en)
|
2023-09-06 |
2025-03-13 |
Afyx Development A/S |
Compositions and methods for treating and preventing oral cancer
|
|
WO2025096738A1
(en)
|
2023-11-01 |
2025-05-08 |
Incyte Corporation |
Kras inhibitors
|
|
WO2025122470A1
(en)
|
2023-12-04 |
2025-06-12 |
Genentech, Inc. |
Combination therapies for treatment of breast cancer
|
|
WO2025129002A1
(en)
|
2023-12-13 |
2025-06-19 |
Incyte Corporation |
Bicyclooctane kras inhibitors
|
|
WO2025202854A1
(en)
|
2024-03-27 |
2025-10-02 |
Pfizer Inc. |
Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
|